Hybrid bacteriophage platforms for the production of non-invasive, self-adjuvanted, and targeted DNA vaccines against SARS-CoV-2

Our project aims to design and develop COVID19 vaccines engineered from viruses that infect bacterial cells only. SARS-CoV2 pathogenic components have been identified and modified to develop the vaccine. Although these components are pathogenic in nature, they are modified to pose no harm. The vaccine is designed to be administered intranasally, where it relocates to […]

Read More